Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.
Martin J. van den Bent(Erasmus MC Cancer Institute), Warren Mason(Princess Margaret Cancer Centre), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), Wolfgang Wick(Heidelberg University), Pim J. French(Erasmus MC Cancer Institute), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Sara Erridge(The University of Texas MD Anderson Cancer Center), Mircea Tesileanu(Erasmus MC Cancer Institute), Kenneth Aldape(National Institutes of Health), Marc Sanson(Centre National de la Recherche Scientifique), Golfinopoulos Vassilis(European Organisation for Research and Treatment of Cancer), Johan M. Kros(Erasmus MC), Brigitta G. Baumert(Kantonsspital Graubünden), Helen Wheeler(The University of Sydney), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum
Cited by 5
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Paraneoplastic anti– <i>N</i> ‐methyl‐ <scp>D</scp> ‐aspartate receptor encephalitis associated with ovarian teratoma
|Annals of Neurology|2007|2.5k